SPANXA2 and cancer: Interestingly, 92% of the sequenced RT-PCR products from different tumors and cancer cell lines corresponded to SPANX-N1 while only 3.3% of the clones from normal tissues corresponded to SPANX-N1 (mostly in testis), suggesting preferable expression of this gene in malignant tissues (Table 2).